Announcements
- Mendus presenterar framsteg med NK-cellsprogrammet på Innate Killer Summit
- Mendus to present NK cell program progress at the Innate Killer Summit
- Mendus erhåller avsiktsförklaringar från större ägare och styrelse samt bolagsledning avseende nyttjande av teckningsoptioner av serie TO3
- Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3
- Nyttjandeperioden för teckningsoptioner av serie TO3 inleds idag
- The exercise period for warrants of series TO3 commences today
- Mendus ger verksamhetsuppdatering och presenterar utsikter för vididencel-programmet
- Mendus provides business update and outlook for vididencel program
- Mendus to participate in upcoming industry conferences
- Mendus medverkar på flera branschkonferenser
More ▼
Key statistics
On Tuesday, Mendus AB (publ) (1YG0:FRA) closed at 0.792, -41.07% below its 52-week high of 1.34, set on Jan 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.792 |
---|---|
High | 0.792 |
Low | 0.792 |
Bid | -- |
Offer | -- |
Previous close | 0.792 |
Average volume | 0.00 |
---|---|
Shares outstanding | 50.36m |
Free float | 23.24m |
P/E (TTM) | -- |
Market cap | 460.29m SEK |
EPS (TTM) | -1.59 SEK |
Data delayed at least 15 minutes, as of Jun 25 2024 07:05 BST.
More ▼